Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y.
Kramer MS, et al.
Neuropsychopharmacology. 2004 Feb;29(2):385-92. doi: 10.1038/sj.npp.1300260.
Neuropsychopharmacology. 2004.
PMID: 14666114
Clinical Trial.